253 related articles for article (PubMed ID: 15863306)
1. In vitro advanced antimycobacterial screening of isoniazid-related hydrazones, hydrazides and cyanoboranes: part 14.
Maccari R; Ottanà R; Vigorita MG
Bioorg Med Chem Lett; 2005 May; 15(10):2509-13. PubMed ID: 15863306
[TBL] [Abstract][Full Text] [Related]
2. In vitro antimycobacterial activities of 2'-monosubstituted isonicotinohydrazides and their cyanoborane adducts.
Maccari R; Ottanà R; Monforte F; Vigorita MG
Antimicrob Agents Chemother; 2002 Feb; 46(2):294-9. PubMed ID: 11796333
[TBL] [Abstract][Full Text] [Related]
3. In vitro advanced antimycobacterial screening of cobalt(II) and copper(II) complexes of fluorinated isonicotinoylhydrazones.
Maccari R; Ottanà R; Bottari B; Rotondo E; Vigorita MG
Bioorg Med Chem Lett; 2004 Dec; 14(23):5731-3. PubMed ID: 15501030
[TBL] [Abstract][Full Text] [Related]
4. New series of isoniazid hydrazones linked with electron-withdrawing substituents.
Vavříková E; Polanc S; Kočevar M; Košmrlj J; Horváti K; Bosze S; Stolaříková J; Imramovský A; Vinšová J
Eur J Med Chem; 2011 Dec; 46(12):5902-9. PubMed ID: 22018878
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, in vitro and in vivo antimycobacterial activities of diclofenac acid hydrazones and amides.
Sriram D; Yogeeswari P; Devakaram RV
Bioorg Med Chem; 2006 May; 14(9):3113-8. PubMed ID: 16412646
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and in vitro and in vivo antimycobacterial activity of isonicotinoyl hydrazones.
Sriram D; Yogeeswari P; Madhu K
Bioorg Med Chem Lett; 2005 Oct; 15(20):4502-5. PubMed ID: 16115763
[TBL] [Abstract][Full Text] [Related]
7. Activity of a new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis.
De Logu A; Onnis V; Saddi B; Congiu C; Schivo ML; Cocco MT
J Antimicrob Chemother; 2002 Feb; 49(2):275-82. PubMed ID: 11815568
[TBL] [Abstract][Full Text] [Related]
8. Development of antitubercular compounds based on a 4-quinolylhydrazone scaffold. Further structure-activity relationship studies.
Gemma S; Savini L; Altarelli M; Tripaldi P; Chiasserini L; Coccone SS; Kumar V; Camodeca C; Campiani G; Novellino E; Clarizio S; Delogu G; Butini S
Bioorg Med Chem; 2009 Aug; 17(16):6063-72. PubMed ID: 19620006
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and in vitro antitubercular activity of ferrocene-based hydrazones.
Mahajan A; Kremer L; Louw S; Guérardel Y; Chibale K; Biot C
Bioorg Med Chem Lett; 2011 May; 21(10):2866-8. PubMed ID: 21507641
[TBL] [Abstract][Full Text] [Related]
10. Isoniazid-related copper(II) and nickel(II) complexes with antimycobacterial in vitro activity. Part 9.
Bottari B; Maccari R; Monforte F; Ottanà R; Rotondo E; Vigorita MG
Bioorg Med Chem Lett; 2000 Apr; 10(7):657-60. PubMed ID: 10762047
[TBL] [Abstract][Full Text] [Related]
11. Rational design of new antituberculosis agents: receptor-independent four-dimensional quantitative structure-activity relationship analysis of a set of isoniazid derivatives.
Pasqualoto KF; Ferreira EI; Santos-Filho OA; Hopfinger AJ
J Med Chem; 2004 Jul; 47(15):3755-64. PubMed ID: 15239654
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, anti-tuberculosis activity, and 3D-QSAR study of 4-(adamantan-1-yl)-2-substituted quinolines.
Nayyar A; Monga V; Malde A; Coutinho E; Jain R
Bioorg Med Chem; 2007 Jan; 15(2):626-40. PubMed ID: 17107805
[TBL] [Abstract][Full Text] [Related]
13. Mechanistic investigation of the oxidation of hydrazides: implications for the activation of the TB drug isoniazid.
Amos RI; Gourlay BS; Yates BF; Schiesser CH; Lewis TW; Smith JA
Org Biomol Chem; 2013 Jan; 11(1):170-6. PubMed ID: 23165368
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity.
Martins F; Santos S; Ventura C; Elvas-Leitão R; Santos L; Vitorino S; Reis M; Miranda V; Correia HF; Aires-de-Sousa J; Kovalishyn V; Latino DA; Ramos J; Viveiros M
Eur J Med Chem; 2014 Jun; 81():119-38. PubMed ID: 24836065
[TBL] [Abstract][Full Text] [Related]
15. Development of isoniazid-NAD truncated adducts embedding a lipophilic fragment as potential bi-substrate InhA inhibitors and antimycobacterial agents.
Delaine T; Bernardes-Génisson V; Quémard A; Constant P; Meunier B; Bernadou J
Eur J Med Chem; 2010 Oct; 45(10):4554-61. PubMed ID: 20696503
[TBL] [Abstract][Full Text] [Related]
16. Four hydrazide compounds that inhibit the growth of mycobacterium tuberculosis.
Bartzatt R; Cirillo SL; Cirillo JD
Physiol Chem Phys Med NMR; 2008; 40():55-65. PubMed ID: 20070040
[TBL] [Abstract][Full Text] [Related]
17. Peptide conjugates of therapeutically used antitubercular isoniazid-design, synthesis and antimycobacterial effect.
Horváti K; Mezo G; Szabó N; Hudecz F; Bosze S
J Pept Sci; 2009 May; 15(5):385-91. PubMed ID: 19319854
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and antitubercular activities of substituted benzoic acid N'-(substituted benzylidene/furan-2-ylmethylene)-N-(pyridine-3-carbonyl)-hydrazides.
Kumar P; Narasimhan B; Yogeeswari P; Sriram D
Eur J Med Chem; 2010 Dec; 45(12):6085-9. PubMed ID: 20828886
[TBL] [Abstract][Full Text] [Related]
19. Antimycobacterial activity of novel N-(substituted)-2-isonicotinoylhydrazinocarbothioamide endowed with high activity towards isoniazid resistant tuberculosis.
Sriram D; Yogeeswari P; Yelamanchili Priya D
Biomed Pharmacother; 2009 Jan; 63(1):36-9. PubMed ID: 18343086
[TBL] [Abstract][Full Text] [Related]
20. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
